What is CAGR? What does CAGR table indicate for Eris Lifesciences Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Eris Lifesciences Ltd Stock Analysis

Q: Is the current market price of Eris Lifesciences Ltd a good price to buy it?

The 5-year analysis of Eris Lifesciences Ltd's performance infers.

Q: What is Eris Lifesciences Ltd share price return in the past 10 years?

We analysed the performance of Eris Lifesciences Ltd share prices over the last 10 years. Here is what we found out:

Mid Cap

Evaluated by 975 users | BSE: 540596 | NSE: ERIS |
Pharmaceuticals & Drugs

10 Year X-Ray

Consolidated basis Standalone basis P Consolidated basis P

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Eris Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Capital Employed	0	65.21%	68.86%	46.12%	38.4%	45.89%	51.59%	30.71%	23.41%	22.31%

Growth Parameters	Growth Parameters Colour Code Guide

Net Sales (Rs. Cr.)	0	274	393	509	546	597	750	856	982	1,074
Y-o-Y Gr. Rt.	-	NA	43.5%	29.5%	7.2%	9.4%	25.5%	14.2%	14.8%	9.4%
Adjusted EPS (Rs.)	0	2,685.13	4,250.65	4,936.57	6,320.32	9,569.04	16.73	20.16	21.02	21.58
Y-o-Y Gr. Rt.	-	NA	58.3%	16.1%	28%	51.4%	-99.8%	20.5%	4.3%	2.7%
Book Value per Share (Rs.)	0	3,470.29	7,687.54	12,817.54	19,278.55	21,711.81	41.25	62.64	83.58	95.26
Adjusted Net Profit	0	36.9	58.5	67.9	86.9	132	230	277	289	293
Net Op. Cash Flow (Rs. Cr.)	0	30.1	38	89.6	90.1	131	200	235	223	271
Debt to Cash Flow from Ops	0	0.17	0.07	0.01	0.01	0	0	1.61	0.79	0

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Eris Lifesciences Ltd. ?

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

Eris Lifesciences Ltd. should be analysed on a Consolidated basis

CAGR CAGR Colour Code Guide

	9 yrs	5 yrs	3 yrs	1 yr
Net Sales	NA	14.5%	12.7%	9.4%
Adjusted EPS	NA	-67.9%	8.9%	2.7%
Book Value per Share	0	-65.4	32.2	14
Share Price	-	-	-8.8%	44.4%

Key Financial Parameter	Performance Ratio Colour Code Guide

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Equity (%)	0	77.09	75.92	47.98	39.24	46.52	53.09	38.82	28.74	23.96
Operating Profit Margin (%)	0	21.38	22.01	19.46	22.26	28.77	35.93	37.65	35.17	34.66
Net Profit Margin (%)	0	13.52	14.93	13.36	15.93	22.25	30.67	32.51	29.47	27.29
Debt to Equity	0	0.1	0.02	0	0	0	0	0.44	0.15	0
Working Capital Days	0	0	69	71	71	68	77	101	118	130
Cash Conversion Cycle	0	0	14	10	8	12	11	-4	-4	10

Management X-Ray

Shareholding Pattern

Entity	Percentage Holding
Promoters	54.23%
Institutions	21.56%
Non-Institutions	24.22%

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

FAQs

1. Is Eris Lifesciences Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Eris Lifesciences Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Eris Lifesciences Ltd is a good quality company. However, for specific investment actions please connect with your investment advisor.

2. Is current market price of Eris Lifesciences Ltd a good price to buy it?

Data is not available for this company.

3. What is Eris Lifesciences Ltd share price return in the past 10 years ?

Data is not available for this company

About Company

Eris Lifesciences founded by Mr Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroenterology and gynaecology. The company’s focus has been on developing, manufacturing and marketing products which are linked to lifestyle related disorders that are chronic in nature and are treated by

The company’s core commitment is towards improving health care outcomes and adding value for all its stakeholders including patients, doctors, regulators, employees and business partners. The company is making ongoing efforts to innovate its products to bring the best clinical practices in health care industry to its customers.

The company’s product portfolio is primarily focused on therapeutic areas which are treated by super-specialist and specialist doctors such as Diabetologists, Endocrinologists, Cardiologists, Gastroenterologists, and Neurologists.

Business area of the company

The company develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives. Its focus has been on developing products in the chronic and acute category which are linked to lifestyle related disorders.

History and milestones

2007: Incorporation of the company.
2007: Launched “Eris” division focused on cardiology and diabetes segment.
2008: Launched “Nikkos” division focused on gastroenterology and orthopedics segment.
2009: Launched “Adura” division focused on cardiology and diabetes segment.
2011: Launched “Montana” division focused on gynecology and pediatrics segment.
2012: Launched “Inspira” division focused on cardiology segment.
2014: Launched “Victus” division focused on anti-diabetes segment.
2014: Set up Assam Facility by the company.
2015: Launched “Eris 2” division focused on pain management segment.
2016: Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited).
2016: Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
2016: Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.
2017: Acquired the trademarks ‘UNION’, ‘REUNION’ and ‘BON UNION’.
2017: Eris acquires 40 trademarks from Amay Pharma
2017: Eris acquires Pune based UTH Healthcare.
2018: Eris entered into a distribution agreement with India Medtronic Private Limited.
2019: Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn.
2019: Eris partners with Pharmanutra S.P.A of Italy for Sideral.